Predictors of Placebo Response in Pharmacological Clinical Trials of Negative Symptoms in Schizophrenia: A Meta-regression Analysis
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Predictors of Placebo Response in Pharmacological Clinical Trials of Negative Symptoms in Schizophrenia: A Meta-regression Analysis
Authors
Keywords
-
Journal
SCHIZOPHRENIA BULLETIN
Volume -, Issue -, Pages -
Publisher
Oxford University Press (OUP)
Online
2017-12-19
DOI
10.1093/schbul/sbx192
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of the glycine transporter type-1 inhibitor AMG 747 for the treatment of negative symptoms associated with schizophrenia
- (2017) Eduardo Dunayevich et al. SCHIZOPHRENIA RESEARCH
- Treatment of negative symptoms: Where do we stand, and where do we go?
- (2017) André Aleman et al. SCHIZOPHRENIA RESEARCH
- Placebo Response and Practice Effects in Schizophrenia Cognition Trials
- (2017) Richard S. E. Keefe et al. JAMA Psychiatry
- Mental disorders of known aetiology and precision medicine in psychiatry: a promising but neglected alliance
- (2016) D. Fraguas et al. PSYCHOLOGICAL MEDICINE
- Strengths and limitations of industry vs. academic randomized controlled trials
- (2015) P.-F. Laterre et al. CLINICAL MICROBIOLOGY AND INFECTION
- Supplementation of antipsychotic treatment with sarcosine – GlyT1 inhibitor – causes changes of glutamatergic 1NMR spectroscopy parameters in the left hippocampus in patients with stable schizophrenia
- (2015) Dominik Strzelecki et al. NEUROSCIENCE LETTERS
- Placebo Effects in Medicine
- (2015) Ted J. Kaptchuk et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expectancies of success as a predictor of negative symptoms reduction over 18 months in individuals with schizophrenia
- (2015) Lauren Luther et al. PSYCHIATRY RESEARCH
- Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia: A 24-Week Double-Blind, Randomized, Parallel, Placebo-Controlled Trial
- (2015) Judith Usall et al. SCHIZOPHRENIA BULLETIN
- Antidepressants versus placebo in major depression: an overview
- (2015) Arif Khan et al. World Psychiatry
- Negative symptoms in schizophrenia: a study in a large clinical sample of patients using a novel automated method
- (2015) Rashmi Patel et al. BMJ Open
- Association Between Placebo-Activated Neural Systems and Antidepressant Responses
- (2015) Marta Peciña et al. JAMA Psychiatry
- Predictors of placebo response in pharmacological and dietary supplement treatment trials in pediatric autism spectrum disorder: a meta-analysis
- (2015) A Masi et al. Translational Psychiatry
- The Selective Glycine Uptake Inhibitor Org 25935 as an Adjunctive Treatment to Atypical Antipsychotics in Predominant Persistent Negative Symptoms of Schizophrenia
- (2014) Joep H. Schoemaker et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Do negative symptoms of schizophrenia change over time? A meta-analysis of longitudinal data
- (2014) M. Savill et al. PSYCHOLOGICAL MEDICINE
- Rasagiline in the Treatment of the Persistent Negative Symptoms of Schizophrenia
- (2014) Robert W. Buchanan et al. SCHIZOPHRENIA BULLETIN
- Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized Placebo-Controlled Trials
- (2014) Paolo Fusar-Poli et al. SCHIZOPHRENIA BULLETIN
- Use of placebo controls in the evaluation of surgery: systematic review
- (2014) K. Wartolowska et al. BMJ-British Medical Journal
- Effect of Bitopertin, a Glycine Reuptake Inhibitor, on Negative Symptoms of Schizophrenia
- (2014) Daniel Umbricht et al. JAMA Psychiatry
- Placebo Response in Antipsychotic Clinical Trials
- (2014) Bret R. Rutherford et al. JAMA Psychiatry
- Meta-Regression Analysis of Placebo Response in Antipsychotic Trials, 1970–2010
- (2013) Ofer Agid et al. AMERICAN JOURNAL OF PSYCHIATRY
- A proposal for an updated neuropsychopharmacological nomenclature
- (2013) Joseph Zohar et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Defining and measuring negative symptoms of schizophrenia in clinical trials
- (2013) Stephen R. Marder et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- No Effects of Antidepressants on Negative Symptoms in Schizophrenia
- (2013) Kim Hinkelmann et al. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
- Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia
- (2013) Stephen R. Marder et al. SCHIZOPHRENIA RESEARCH
- Pomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo
- (2013) Virginia L. Stauffer et al. SCHIZOPHRENIA RESEARCH
- A Multicenter, Add-On Randomized Controlled Trial of Low-Dosed-Serine for Negative and Cognitive Symptoms of Schizophrenia
- (2012) Mark Weiser et al. JOURNAL OF CLINICAL PSYCHIATRY
- Negative symptoms have greater impact on functioning than positive symptoms in schizophrenia: Analysis of CATIE data
- (2012) Jonathan Rabinowitz et al. SCHIZOPHRENIA RESEARCH
- Raloxifene as an Adjunctive Treatment for Postmenopausal Women With Schizophrenia
- (2011) Judith Usall et al. JOURNAL OF CLINICAL PSYCHIATRY
- Negative expectancy appraisals and defeatist performance beliefs and negative symptoms of schizophrenia
- (2011) Shannon M. Couture et al. PSYCHIATRY RESEARCH
- Folate supplementation in schizophrenia: A possible role for MTHFR genotype
- (2011) Michele Hill et al. SCHIZOPHRENIA RESEARCH
- Does Inclusion of a Placebo Arm Influence Response to Active Antidepressant Treatment in Randomized Controlled Trials?
- (2010) Mark Sinyor et al. JOURNAL OF CLINICAL PSYCHIATRY
- The environment and schizophrenia
- (2010) Jim van Os et al. NATURE
- Voxel-wise meta-analysis of grey matter changes in obsessive–compulsive disorder
- (2009) Joaquim Radua et al. BRITISH JOURNAL OF PSYCHIATRY
- Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD
- (2008) George I. Papakostas et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Feasibility of Reducing the Duration of Placebo-Controlled Trials in Schizophrenia Research
- (2008) Robert P. McMahon et al. SCHIZOPHRENIA BULLETIN
- What Is Causing the Reduced Drug-Placebo Difference in Recent Schizophrenia Clinical Trials and What Can be Done About It?
- (2008) A. S. Kemp et al. SCHIZOPHRENIA BULLETIN
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now